Zobrazeno 1 - 10
of 829
pro vyhledávání: ''
Autor:
D. Feng, David Maag, Banu Arun, Shannon Puhalla, S. Bhattacharya, Madan Gopal Kundu, N. Khandelwal, Christine K. Ratajczak, Hans Wildiers, Bruce A. Bach, Véronique Diéras, J.P. Ayoub, Hyo S. Han, Michael Friedlander, Bella Kaufman
Publikováno v:
Annals of Oncology. 33:299-309
BACKGROUND: In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with
Autor:
Dirk Waldschmidt, J-B. Bachet, Lawrence Fong, J. Tabernero, Michele Reni, H-M. Chang, Sara Lonardi, G. Cole, Margaret A. Tempero, Andrew Eugene Hendifar, D-Y. Oh, L.C. Tsao, Teresa Macarulla, Danelle F. James, E. Van Cutsem, Juan Maurel, Lisa M. Coussens, Naureen Starling, Rocio Garcia-Carbonero
Publikováno v:
Scientia
Ibrutinib; Metastatic pancreatic adenocarcinoma; Phase III Ibrutinib; Adenocarcinoma de páncreas metastásico; Fase III Ibrutinib; Adenocarcinoma de pàncrees metastàtic; Fase III First-line treatment of metastatic pancreatic ductal adenocarcinoma
Autor:
W.S. Kim, Jin Soo Kim, T. Kim, Ho-Young Yhim, D.-H. Yang, H.-J. Shin, G.S. Park, Jinny Park, S.J. Kim, Joon Ho Moon, Youngil Koh
Publikováno v:
Annals of Oncology. 32:552-559
Background Current treatment options for peripheral T-cell lymphomas (PTCLs) in the relapsed/refractory setting are limited and demonstrate modest response rates with rare achievement of complete response (CR). Patients and methods This phase I/II st
Autor:
William A. Wegener, David M. Goldenberg, RL Moroose, Joyce O'Shaughnessy, Dejan Juric, Aditya Bardia, Sara M. Tolaney, Jennifer R. Diamond, Vandana G. Abramson, Ingrid A. Mayer, Pius Maliakal, Linda T. Vahdat, T. Goswami, Kevin Kalinsky, Robert M. Sharkey, Q. Hong
Publikováno v:
Ann Oncol
Background Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody–drug conjugate composed of a
Autor:
Joohyuk Sohn, S.-B. Kim, Konstantinos Tryfonidis, A. Wang, Peter Schmid, Eva Muñoz-Couselo, Lina Yin, Roberto Salgado, Rebecca Dent, Sherene Loi, S-A. Im, Vassiliki Karantza, J. Cortes, Sherko Kuemmel, Theodoros Foukakis, Younghee Park
Publikováno v:
Annals of Oncology. 31:569-581
Background The phase Ib KEYNOTE-173 study was conducted to assess the safety and preliminary antitumor activity of neoadjuvant chemotherapy plus pembrolizumab in high-risk, early-stage, non-metastatic triple-negative breast cancer (TNBC). Patients an
Autor:
H. J. Lenz, T. Yoshino
Publikováno v:
Annals of Oncology. 31:1085-1087
Autor:
J.H. Hong, Y.S. Park, Myung Ah Lee, Sung Heon Kim, J.W. Lee, So Young Yoon, Seungtae Kim, Jung-Hun Kang, J. O. Park, Joung-Soon Jang, Byeong Seok Sohn, S.Y. Oh, Hyungwoo Lee, M. Kim, H. Y. Lim, Hye Jin Choi
Publikováno v:
Annals of Oncology. 30:788-795
Background Capecitabine plus oxaliplatin (XELOX) has shown modest activity and tolerable toxicity in a phase II trial for biliary tract cancers (BTCs). Meanwhile, gemcitabine plus oxaliplatin (GEMOX) has been the reference arm in recent phase II and
Autor:
Y-K. Kang, L.-T. Chen, Hiroki Hara, Yoshito Komatsu, Masahiro Tsuda, Ken Kato, Hyun Cheol Chung, Mizutomo Azuma, Narikazu Boku, H. Cho, Kensei Yamaguchi, Soichi Fumita, Won Ki Kang, Keun Wook Lee, Min-Hee Ryu, Keiko Minashi
Publikováno v:
Annals of Oncology
Background Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy of first-line therapy,
Publikováno v:
Annals of Oncology
Background: In the COVID-19 era, a simplified risk assessment algorithm for CIN might optimize resource utilization. Since Gr4N toxicity is frequently measured and reported in clinical trial results, Gr4N frequency might predict adverse clinical outc
Publikováno v:
Annals of Oncology. 29:1903-1910
The use of supportive granulocyte colony-stimulating factor (G-CSF) to reduce the risk of neutropenic complications in high-risk cancer patients is consistently recommended by several clinical practice guidelines. However, in a previous meta-analysis